Cicada variant BA.3.2 under surveillance as COVID-19 cases trend downward
The emergence of a new COVID-19 variant, designated BA.3.2 and informally referred to as “Cicada,” is capturing attention as health organizations monitor its spread and potential impact. Contrary to its name, which is associated with noisy insects, the variant is a subject of scientific scrutiny rather than seasonal emergence.
Variant Identification and Spread
First identified in November 2024, BA.3.2 has since been detected in at least 23 countries and is present in approximately 25 states throughout the United States as of February. While the variant is spreading, it has not yet become the dominant strain, a point emphasized by Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University. “Whether it will push itself to the front of the line remains to be seen,” Schaffner stated, indicating that ongoing observation will be crucial in evaluating its trajectory.
Understanding BA.3.2’s Characteristics
Belonging to the Omicron family of COVID-19 variants, BA.3.2 is notable for having between 70 and 75 mutations. A recent study published in The Lancet indicates that existing COVID-19 vaccines generally offer less effectiveness against this new variant compared to those that target currently dominant strains. However, some level of protection is still afforded by the vaccines.
According to Schaffner, the findings suggest an emerging capacity for BA.3.2 to evade some immune defenses built up over time. “These are still early days. At the moment, the conclusion seems to be that this new variant can evade some of the protections we have all acquired over the years,” he noted.
Current Impact on Health Systems
Despite the introduction of BA.3.2, there has not been a nationwide uptick in severe COVID-19 cases in the United States. Public health data shows a general decline in case rates, emergency room visits, and hospitalizations. However, local variations are evident, with states like Massachusetts and Florida potentially experiencing rises in COVID-19 cases.
Dr. Celine Gounder, a medical contributor, confirmed that “we haven’t seen evidence of this variant causing more severe disease or an increase in hospitalizations elsewhere.” This assertion may provide some reassurance as health authorities engage in ongoing analysis of the variant’s implications for public health.
Symptoms and Recommendations
Common symptoms associated with COVID-19, such as fever, cough, shortness of breath, sore throat, and congestion, continue to be reported. In light of ongoing threats posed by variants like BA.3.2, public health officials stress the importance of vaccination, particularly among high-risk groups. The Centers for Disease Control and Prevention (CDC) recommends that individuals aged 65 and older, as well as those with underlying health conditions or who are immunocompromised, stay up to date with their vaccinations.
Schaffner advises that high-risk individuals consider receiving a booster dose towards the end of May or the beginning of June, as this timing may help provide protection against any potential summer increases in COVID-19 cases, a trend observed in previous years.
Conclusion
As the BA.3.2 variant continues to circulate internationally and domestically, the focus remains on understanding its characteristics, impacts on public health, and potential responses. Ongoing research and vigilant surveillance will be key in determining how this new strain fits into the broader context of the COVID-19 pandemic.
Source: Original Reporting
About The Author
